Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 1/2 2Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Sarcoma 2Pancreatic Neoplasms 1

Interventions

Gemcitabine 15pembrolizumab 13Doxorubicin 13Radiotherapy 12Docetaxel 9Nivolumab 8Filgrastim 7Cyclophosphamide 7pazopanib 6Ifosfamide 6130-nm albumin-bound paclitaxel 5Temozolomide 4Irinotecan 4Ipilimumab 4Imatinib Mesylate 4Albumin-Bound Paclitaxel 4talimogene laherparepvec 3surufatinib 3pegfilgrastim 3eribulin 3atezolizumab 3Vinorelbine 3Sirolimus 3Peripheral Blood Stem Cell Transplantation 3PM 01183 3Drug Therapy 3Cisplatin 3toripalimab 2spartalizumab 2selinexor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Sarcoma × olaratumab × Clear all
NCT02659020 2022-05-09

ANNOUNCE 2

Eli Lilly and Company

Phase 1/2 Completed
310 enrolled 33 charts
Sarcoma

Sarcoma

NCT01185964 2017-04-14

A Study of Olaratumab in Soft Tissue Sarcoma

Eli Lilly and Company

Phase 1/2 Completed
148 enrolled 21 charts
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡